

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of

COSME ET AL

Serial No. 10/516,338

Filed: November 30, 2004

For: METHODS OF PURIFICATION OF CYTOCHROME P450  
PROTEINS AND OF THEIR CRYSTALLIZING



Atty. Ref.: 620-347

Group: 1645

Examiner: Unassigned

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

June 28, 2005

Sir:

**INFORMATION DISCLOSURE STATEMENT**

- ☒ 1. **PTO-1449 Pursuant to 37 CFR 1.97(b)**  
[within 3 months of filing or prior to 1st Office Action on the merits]  
N/C
- ☐ 2.(a) **Statement Pursuant to 37 CFR 1.97(c)**  
[before Final Office Action or Allowance (requires Rule 97(e)  
Statement or Rule 17(p) fee)]  
N/C
- ☐ 2.(b) **Fee Payment Pursuant to 37 CFR 1.97(c)**  
[before Final Office Action or Allowance (requires Rule 97(e)  
Statement or Rule 17(p) fee)]  
\$180.00
- ☐ 3. **Pursuant to 37 CFR 1.97(d)**  
[after Final Office Action or Allowance (requires Rule 97(e)  
Statement and Rule 17(p) fee), but before final fee payment]  
\$180.00

The following are submitted in the above-identified application in compliance with 37 C.F.R. §§ 1.97 and 1.98:

- ☒ 4. A list of documents on Form PTO-1449 together with copies of each identified document and a translation or a concise explanation of each non-English language document (such as a Search Report) is enclosed herewith.


This paper is submitted in accordance with:

- ☒ 5. 37 CFR 1.97(b): [within 3 months of filing or prior to 1st Office Action]
- ☐ 6. 37 CFR 1.97(c): [before Final Office Action or Allowance, whichever is earlier]; and
- ☐ a) The required Statement made in item 8 below; or
- ☐ b) The \$180.00 fee specified in 37 CFR §1.17(p) for submission of this Information Disclosure Statement is authorized in item 9 below.
- ☐ 7. 37 CFR §1.97(d): [after Final Office Action or Allowance (requires Rule 97(e) Statement and Rule 17(p) fee), but before final fee payment]; and
- ☐ a) The fee (\$180.00) required by 37 CFR §1.17(p) is submitted herewith; and
- ☐ b) The required Statement is stated in item 8 below.
- ☐ 8. Statement under 37 CFR 1.97(e)
- ☐ a) The undersigned attorney of record hereby certifies under 37 C.F.R. §1.97(e) that each item of information contained in this Information Disclosure Statement was first cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this Information Disclosure Statement (each item contained in this IDS was the first citation of that item by a foreign patent office in a counterpart foreign application which occurred no more than three months prior to the filing of this IDS); or
- ☐ b) No item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing this Statement, after making reasonable inquiry, no item of information contained in this Statement was known to any individual designated in 37 CFR §1.56(c) more than three months prior to the filing of this Information Disclosure Statement.

- ☒ 9. Please charge all deficiency fees associated with the submission of this Information Disclosure Statement and any other fees applicable to this application to Deposit Account No. 14-1140. An original and one (1) copy of this document are enclosed.

Respectfully submitted,  
NIXON & VANDERHYE P.C.

By: \_\_\_\_\_

  
B. J. Sadoff

Reg. No. 36,663

1100 North Glebe Road, 8th Floor  
Arlington, VA 22201-4714  
Telephone: (703) 816-4000  
Facsimile: (703) 816-4100

**INFORMATION DISCLOSURE  
CITATION**

ATTY. DOCKET NO.

SERIAL NO.

620-347

10/516,338

APPLICANT

COSME ET AL

FILING DATE

GROUP

November 30, 2004

1645

**U.S. PATENT DOCUMENTS**

*EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	6,312,917	11/2001	Thakker et al.			
	6,432,639	08/2002	Lichter et al.			

**FOREIGN PATENT DOCUMENTS**

DOCUMENT		DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
						YES	NO
	DE 195 49 267	07/1997	Germany				
	WO 99/08812	02/1999	WIPO				

**OTHER DOCUMENTS (including Author, Title, Date, Pertinent pages, etc.)**

	Armelle Melet et al.; <i>Archives of Biochemistry and Biophysics</i> , Volume 409, Issue 1, 1 January 2003, Pages 80-91.
	Cheng-Chung Tsao et al.; <i>Biochemistry</i> ; <b>2001</b> ; 40(7), 1937 – 1944
	Dansette, Patrick M.; Universite Rene Descartes, Paris, France. Abstract/Poster 81. <b>Sulphenazole Derivatives as Tools for Comparing CYP 2C5 and Human 2C's: Identification of a New High Affinity Substrate (DMZ) Common to Those CYP 2C Enzymes.</b>
	Ekins, S. et al.; <i>J. Pharmacol. Exp Ther.</i> ; 1999; 290(1); 429-38
	Ekins, S. et al.; <i>J. Pharmacol. Exp Ther.</i> ; 1999; 291(1); 424-33
	Guengerich, F.P. et al.; <i>Annu. Rev. Pharmacol. Toxicol.</i> ; 1999; 39; 1-17
	He M et al.; <i>Arch Biochem Biophys.</i> 1999 Dec 1;372(1):16-28.
	Hosea NA et al.; <i>Biochemistry</i> ; 2000; 39(20), 5929-39
	Hutzler, J.M. et al.; <i>Archives of Biochemistry and Biophysics</i> ; <b>2003</b> , 410, 16-24.
	Hutzler, J.M. et al.; <i>Drug Metabolism and Disposition</i> , <b>2002</b> , Vol 30, pp 1194-1200.
	Hutzler, J.M. et al.; <i>Drug Metabolism and Disposition</i> , <b>2001</b> , Vol 29, 1029-1034.
	Johnson, Eric; Scripps Research Institute, La Jolla, CA, USA. Abstract 4. <b>Structural Characterisation of Substrate and Inhibitor Binding to 2C P450s.</b>
	Kaminsky LS, Zhang ZY.; <i>Pharmacol Ther.</i> 1997;73(1):67-74.
	Korzekwa, K.R et al.; <i>Biochemistry</i> ; <b>1998</b> , Vol 37, 4137-4147.
	Kunze KL et al.; <i>Drug Metab Dispos.</i> 1996 Apr;24(4):414-21.
	Lewis, DF et al.; <i>Xenobiotica</i> ; 1996; 26(10); 1067-86

\*Examiner

Date Considered

Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to application.

Form PTO-FB-A820 (Also PTO-1449)

## INFORMATION DISCLOSURE

## CITATION

ATTY. DOCKET NO.

SERIAL NO.

620-347

10/516,338

APPLICANT

COSME ET AL

FILING DATE

GROUP

November 30, 2004

1645

## U.S. PATENT DOCUMENTS

*EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE

## FOREIGN PATENT DOCUMENTS

DOCUMENT	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION YES NO

## OTHER DOCUMENTS (including Author, Title, Date, Pertinent pages, etc.)

	Longenecker KL et al.; <i>Acta Crystallogr D Biol Crystallogr</i> ; 2001, 57(Pt 5), 679-88
	Mansuy, Daniel; Universite Rene Descartes, Paris, France. Abstract 5. <b>Origin of Substrate Specificity of Cytochromes P450 2C: Chemical and Biochemical Approaches.</b>
	Marques-Soares, C. et al; <i>Biochemistry</i> ; 2003; 42(21); 6363-6369
	Ravichandran K G et al., <i>Science</i> , vol. 261, pages 731-736, 6 August 1993
	Schoch GA et al; <i>J Biol. Chem.</i> 2004 Mar 5; 279(10): 9497-9503.
	Sevrioukova et al.; PNAS (1999) 96, 1863-8
	Sueyoshi et al.; <i>Archives of Biochemistry and Biophysics</i> ; Vol. 322, No. 1, 1995, pp 265-271
	Szklarz GD; <i>J. Comput Aided Mol. Des.</i> ; 1997; 11(3); 265-72.
	Wester, M. R.; <i>Biochemistry</i> ; 2003; 42(31); 9335-9345.
	Wester, M. R.; et al.; <i>Biochemistry</i> ; 2003; 42(21); 6370-6379.
	Zamora, I.; Afzelius, L.; Cruciani, G.; <i>J. Med. Chem.</i> ; 2003; 46(12); 2313-2324.
	Zamora, Isobel; Lead Molecular Design, S.L. Sant Cugat del Valles, Spain. Abstract/Poster 77. <b>Metabolism Prediction for Cytochrome P450.</b>

*Examiner	Date Considered
-----------	-----------------

Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to application.

Form PTO-FB-A820 (Also PTO-1449)